Diagnosing distressing skin disorders

The Annual Meeting’s scientific program covers a wide selection of topics. Three sessions on Monday, Feb. 19, will engage audience members with the latest information and allow them to walk away with critical diagnostic and treatment skills for troublesome conditions. The AAD Patient Advocate Task Force has worked to bring patients to these educational sessions.

Monday sessions to feature patient participation in addition to audience engagement.

In “Pemphigus and Pemphigoid: Evidence-based Updates” (U079), session director Donna Culton, MD, PhD, will reveal the latest information regarding mechanisms of disease pathogenesis and how these mechanisms point to certain therapies. Dr. Culton will review the efficacy and safety of both established and newer treatment options, including topical steroids, systemic steroids, immunosuppressive agents, intravenous immunoglobulin, and B cell depleting therapies.

Of the 1.7 million people diagnosed with cancer each year, approximately 65% will receive a systemic treatment, including cytotoxic, targeted, or immunotherapeutic agent. In “Dermatologic Side Effects of Anticancer Drugs in 2017: What You Need to Know” (F128), Mario E. Lacouture, MD, will outline critical elements for identifying, preventing, and treating dermatologic adverse events from novel anticancer agents.

The development of Janus kinase inhibitors with their unique mechanism of action has led to new therapeutic options in dermatology. Brett Andrew King, MD, PhD, will present results of clinical trials and overall safety factors in the focus session “Treating Alopecia Areata, Vitiligo, and Atopic Dermatitis: JAK Inhibitors, Something New for Dermatology” (U086). Attendees will learn how to effectively utilize JAK inhibitors, as well as the potential adverse effects.


Return to index